Status:

COMPLETED

Individualized Obesity Pharmacotherapy

Lead Sponsor:

Mayo Clinic

Conditions:

Obesity

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.

Detailed Description

All participants will be phenotype and participants will randomized to randomly assigned medications vs phenotype guided medications for obesity. All participants will receive a standard intense lifes...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Adults with obesity (BMI \>30 Kg/m2); these will be otherwise healthy individuals with no unstable psychiatric disease and controlled comorbidities or other diseases.
  • Gender: Men or women. Women of childbearing potential will have negative pregnancy tests within 48 hours of enrollment and before each radiation exposure.
  • Exclusion criteria
  • Abdominal bariatric surgery
  • Positive history of chronic gastrointestinal diseases, or systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., orlistat, within the last 6 months.
  • Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia). If such a dysfunction is identified by an anxiety or depression score \>11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.
  • Hypersensitivity to any of the study medications.
  • No contraindications to all FDA-approved medications

Exclusion

    Key Trial Info

    Start Date :

    December 11 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 26 2022

    Estimated Enrollment :

    193 Patients enrolled

    Trial Details

    Trial ID

    NCT03374956

    Start Date

    December 11 2017

    End Date

    May 26 2022

    Last Update

    July 18 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Mayo Clinic in Rochester

    Rochester, Minnesota, United States, 55905